Nona Biosciences
Cambridge, MA, United States nonabio.com From their website, Nov 2026
Work here? Claim this listing
About
Nona Biosciences develops discovery, engineering, screening, and development capabilities for antibodies, siRNA, and other next-generation modalities. It serves biopharma teams working on therapeutic candidates from early discovery through IND-enabling stages. The company describes platform technologies including Harbour Mice®, Hu-mAtrIx™, and CAR-based functional screening.
Services
Fully Human Antibody Discovery
Discovery of fully human antibodies using the company's antibody platform technologies.
siRNA Discovery
Discovery support for siRNA therapeutic candidates.
Beacon Single B Cell Screening
Single B cell screening service using Beacon technology.
CAR-based Functional Screening
Functional screening based on CAR systems for antibody and related discovery workflows.
Display Screening
Display-based screening for antibody discovery and selection.
Hybridoma Screening
Screening of hybridoma-derived antibody candidates.
Antibody Engineering Capability
Engineering support for antibody optimization and design.
Bispecific/Multispecific Antibody Engineering
Engineering services for bispecific and multispecific antibodies.
17 more services
- Bispecific Antibody Developability Assessment
- ADC Engineering & Conjugation
- Toxicology and Safety Assessment
- IND-enabling CMC
- mRNA-LNP Delivery
- Blood Brain Barrier Delivery
- In Vivo CAR Delivery
- Oligonucleotide Delivery
- HBICE® – Bi/Multi-specific CAR-based Cell Therapy
- Antibody Drug Conjugates
- mRNA
- TCR Mimic Antibody
- siRNA Therapeutics
- Antibody-Oligonucleotide Conjugates
- Antibody Screening Capabilities
- Targeted Cargo Delivery Systems
- Integrated Idea – IND Program
Capabilities
- Assays and studies
- Antibodies
- Rodent models
- Bispecifics
- ADCs
- mRNA
- Oligonucleotides
13 more
- Cell therapy
- Toxicology
- Hybridoma
- In vivo
- Single B cell screening
- CAR-based functional screening
- Display screening
- Hybridoma screening
- Bispecific antibody developability assessment
- B cell sorting
- Functional screening
- Developability assessment
- Affinity prioritization
- Scale and capacity
- 140+ partners
- 380+ projects
- 20+ IND/Clinical Stage
Instruments and platforms
- Beacon
Modalities and species
- Modalities
- Antibody
- Bispecific
- ADC
- Oligonucleotide
- mRNA
- Cell therapy
- LNP / formulation
- Species and models
- Harbour Mice® HCAb
- Harbour Mice® H2L2
- Mice
- Beacon
- Hybridoma
Industries served
- Biopharma
- Biotech
Details
- Type
- CRDMO
- Based in
- Cambridge, MA, United States
- Serves
- Global